A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM) Wakelee, H. A., Fehling, J. M., Molina, J. R., Lensing, J. L., Funke, R. P., Miles, D., Sikic, B. I. AMER SOC CLINICAL ONCOLOGY. 2008

View details for Web of Science ID 000208457400823